Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.

The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.

Payers want to make sure patients are getting biopsies done so they can get on the right therapies, said Bhuvana Sagar, MD, Oncology Consultants.

The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.